News Releases

The NIH/DAIDS Cross-Network (ACTG/HVTN/IMPAACT) TB Vaccine Working Group calls for people living with HIV to be included in tuberculosis vaccine development

News Releases - October 14, 2022

Newly defined biomarker may accelerate clinical trials for vaccines to prevent HIV-1 infection

A study published in the Aug. 22, 2022 issue of Nature Medicine identifies a new biomarker that appears effective as a surrogate endpoint to reliably predict the ability of broadly neutralizing monoclonal antibodies to prevent acquisition of HIV-1, the most common type of the virus that causes AIDS.

News Releases - August 24, 2022

HVTN at the 24th International AIDS Conference in Montreal

HVTN researchers and faith leaders will address HIV and SARS-CoV-2, neutralizing antibodies, future directions for research, lessons from COVID-19 community engagement, overcoming HIV stigma and discrimination, and more

News Releases - July 28, 2022

CoVPN Trial: Novavax’s Traditional COVID-19 Vaccine Correlates to Strong Antibody Response, Protection Against SARS-CoV-2

Response comparable to mRNA vaccines and if authorized, could help bolster global vaccine supplies

News Releases - June 28, 2022

After Sprint for COVID-19 Vaccines, HVTN Researchers Return to HIV Marathon With Fresh Determination and Knowledge, Launch Clinical Research Registry and Ad Campaign

News Releases - May 18, 2022

Increased support needed for a coordinated global HIV and COVID-19 response

News Releases - March 23, 2022

Trial of innovative HIV vaccine using mRNA technology enrolls first participant

News Releases - March 14, 2022

Preliminary findings from studies in South Africa indicate that Omicron has a much higher rate of asymptomatic 'carriage' than other variants of concern

News Releases - January 07, 2022

Faith initiative expands to help build bridges between community and HIV vaccine trials

News Releases - December 14, 2021

Landmark COVID-19 Vaccine Trial in Sub-Saharan Africa is the first to study the efficacy of MRNA COVID-19 vaccines in people living with HIV

News Releases - December 13, 2021

The NIH/DAIDS Cross-Network (ACTG/HVTN/IMPAACT) TB Vaccine Working Group calls for people living with HIV to be included in tuberculosis vaccine development

Newly defined biomarker may accelerate clinical trials for vaccines to prevent HIV-1 infection

HVTN at the 24th International AIDS Conference in Montreal

CoVPN Trial: Novavax’s Traditional COVID-19 Vaccine Correlates to Strong Antibody Response, Protection Against SARS-CoV-2

After Sprint for COVID-19 Vaccines, HVTN Researchers Return to HIV Marathon With Fresh Determination and Knowledge, Launch Clinical Research Registry and Ad Campaign

Increased support needed for a coordinated global HIV and COVID-19 response

Trial of innovative HIV vaccine using mRNA technology enrolls first participant

Preliminary findings from studies in South Africa indicate that Omicron has a much higher rate of asymptomatic 'carriage' than other variants of concern

Faith initiative expands to help build bridges between community and HIV vaccine trials

Landmark COVID-19 Vaccine Trial in Sub-Saharan Africa is the first to study the efficacy of MRNA COVID-19 vaccines in people living with HIV

Study participants feel good when helping others, HVTN analysis shows

HVTN Remembers Dr. Scott Hammer

Experimental Phase 2B HIV Vaccine Regimen Provides Insufficient Protection in Preventing HIV

Antibody Mediated Prevention (AMP) Trials Data Published by the New England Journal of Medicine

Harmonizing efforts to conduct large scale COVID-19 vaccine efficacy trials

HVTN participates in 23rd international AIDS conference (virtual)

Skilled partners in the conduct of HIV prevention trials join COVID-19 response

Fred Hutch and NIH experts outline plan for COVID-19 vaccines

The HVTN and HPTN remember Gita Ramjee

Public statement by the HIV Vaccine Trials Network (HVTN) on COVID-19, April 2020